HC Wainwright Has Optimistic Opinion of RYTM Q3 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – HC Wainwright boosted their Q3 2026 earnings per share estimates for Rhythm Pharmaceuticals in a research report issued on Monday, October 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.68) for the quarter, up from their prior estimate of ($0.71). HC Wainwright has a “Buy” rating and a $130.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($2.85) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.28) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at $0.14 EPS and FY2027 earnings at ($0.62) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.08. The firm had revenue of $71.25 million during the quarter, compared to the consensus estimate of $67.66 million. Rhythm Pharmaceuticals had a negative return on equity of 159.87% and a negative net margin of 85.59%. The company’s quarterly revenue was up 46.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.75) earnings per share.

A number of other equities analysts have also recently issued reports on RYTM. Royal Bank Of Canada increased their target price on Rhythm Pharmaceuticals from $155.00 to $159.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Wolfe Research began coverage on shares of Rhythm Pharmaceuticals in a research note on Thursday, September 17th. They set an “outperform” rating for the company. National Bank Financial set a $160.00 price target on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 5th. Citigroup restated a “market outperform” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Rhythm Pharmaceuticals from $145.00 to $146.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Seventeen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $142.56.

Rhythm Pharmaceuticals Stock Down 3.6%

Shares of NASDAQ:RYTM opened at $86.61 on Wednesday. Rhythm Pharmaceuticals has a twelve month low of $74.50 and a twelve month high of $122.20. The stock’s 50 day moving average is $103.31 and its 200-day moving average is $97.84.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CEO David Meeker sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the completion of the sale, the chief executive officer directly owned 239,258 shares of the company’s stock, valued at approximately $24,564,618.86. The trade was a 17.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hunter Smith sold 62,774 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $105.46, for a total value of $6,620,146.04. Following the completion of the sale, the chief financial officer directly owned 114,024 shares of the company’s stock, valued at approximately $12,024,971.04. This trade represents a 35.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 258,450 shares of company stock worth $28,796,497. 5.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of RYTM. Pictet Asset Management Holding SA lifted its stake in Rhythm Pharmaceuticals by 8.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 667,046 shares of the company’s stock valued at $57,329,000 after acquiring an additional 52,383 shares in the last quarter. Orbimed Advisors LLC boosted its holdings in Rhythm Pharmaceuticals by 31.0% during the 1st quarter. Orbimed Advisors LLC now owns 314,100 shares of the company’s stock worth $27,317,000 after acquiring an additional 74,300 shares during the last quarter. Nan Fung Group Holdings Ltd purchased a new position in Rhythm Pharmaceuticals during the 2nd quarter worth $5,453,794. Squarepoint Ops LLC grew its stake in shares of Rhythm Pharmaceuticals by 60.8% in the 2nd quarter. Squarepoint Ops LLC now owns 422,921 shares of the company’s stock worth $46,957,000 after acquiring an additional 159,953 shares in the last quarter. Finally, Blue Owl Capital Holdings LP bought a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter worth $6,823,000.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Rhythm announced the commercial launch of IMCIVREE (setmelanotide) in Japan for acquired hypothalamic obesity. The treatment is the first approved therapy in Japan for this condition and is covered under the country’s National Health Insurance drug-price system, creating a new commercial opportunity. Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE in Japan
• Positive Sentiment: Zacks upgraded RYTM to a Rank #2, or Buy, citing improving optimism around the company’s earnings prospects. Such a rating change may support near-term investor interest. Rhythm Pharmaceuticals Upgraded to Buy
• Neutral Sentiment: Recent commentary highlights investor focus on Rhythm’s progress in Prader-Willi syndrome and genetically defined obesity therapies, but provides limited new operating or financial information. Investors May Respond to Rhythm Pharmaceuticals Progress
• Negative Sentiment: HC Wainwright cut its FY2027 EPS forecast to a loss of $0.62 from a projected profit of $0.53. It also lowered estimates for the second and third quarters of 2027 and Q4 2027, signaling slower expected improvement in profitability.
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $2.28 from $2.96 and modestly improved its Q3 and Q4 2026 estimates. The analyst nevertheless retained a Buy rating and $130 target, implying substantial upside from the recently reported trading level.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases of obesity and other disorders involving the melanocortin-4 receptor (MC4R) pathway. The company’s research is centered on conditions in which genetic defects disrupt the body’s regulation of appetite, hunger and energy expenditure.

Rhythm’s lead product is IMCIVREE (setmelanotide), an MC4R agonist designed to restore signaling in the brain’s melanocortin pathway.